Guardant Health, Inc. (GH) intrinsic value & 10-year financials
Guardant Health, Inc. (GH) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 50.2% a year to $982.0M, with an average return on invested capital of 24.6%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $158.60
- Market cap
- $19.9B
- Revenue (FY2025)
- $982.0M
- Revenue growth (10-yr CAGR)
- 50.2%
- ROIC (10-yr avg)
- 24.6%
- Free cash flow (FY2025)
- -$233.1M
GH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $982.0M | -$416.3M | -$3.32 | -$233.1M | -44.5% | -47.2% |
| FY2024 | $739.0M | -$436.4M | -$3.56 | -$274.9M | -60.0% | 602.1% |
| FY2023 | $563.9M | -$479.4M | -$4.28 | -$345.5M | -100.1% | 171.0% |
| FY2022 | $449.5M | -$654.6M | -$6.41 | -$386.9M | -121.1% | -214.6% |
| FY2021 | $373.7M | -$384.8M | -$4.00 | -$284.1M | -110.0% | -92.8% |
| FY2020 | $286.7M | -$246.3M | -$2.60 | -$140.1M | -88.9% | -42.7% |
| FY2019 | $214.4M | -$75.7M | -$0.84 | -$65.9M | -38.4% | -11.7% |
| FY2018 | $90.6M | -$85.1M | — | -$92.4M | -102.5% | -23.5% |
| FY2017 | $49.8M | -$83.2M | — | -$78.9M | -153.7% | -39.5% |
| FY2016 | $25.2M | -$46.1M | — | -$38.5M | -173.7% | -55.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Guardant Health, Inc. is a consistent compounder, expanding top-line revenue at 50.2% annually over the past decade.
Guardant Health, Inc. has historically struggled to out-earn its cost of capital, averaging just -30.7% ROIC.
Guardant Health, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Guardant Health, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-110.28 per share.